ACT-AD Comments Urging the FDA to Continue Making Alzheimer’s Disease a Priority

ACT-AD submitted comments to the U.S. Food and Drug Administration (FDA) on behalf of a number of Alzheimer’s disease stakeholders urging the FDA to continue making Alzheimer’s disease a priority, particularly with respect to their activities to develop a transparent risk/benefit evaluation framework. The comments applaud FDA’s inclusion of patient-focused drug development enhancements in PDUFA V, but encourage FDA to continue considering needs of people with Alzheimer’s disease as the agency implements these enhancements over the next five years.
View Comments

File Attachments